Georgios Schoretsanitis1,2, John M Kane2,3, Christoph U Correll2,3,4, Stephen R Marder5, Leslie Citrome6, John W Newcomer7, Delbert G Robinson2,3, Donald C Goff8, Deanna L Kelly9, Oliver Freudenreich10, Daria Piacentino11, Michael Paulzen12, Andreas Conca13, Gerald Zernig14, Ekkehard Haen15, Pierre Baumann16, Christoph Hiemke17, Gerhard Gründer18, The Therapeutic Drug Monitoring Task Force Of The Arbeitsgemeinschaft Für Neuropsychopharmakologie Und Pharmakopsychiatrie. 1. Department of Psychiatry Research, The Zucker Hillside Hospital, Northwell Health, 75-59 263rd St, Glen Oaks, NY 11004. george.schor@gmail.com. 2. Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, and Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, Manhasset, New York, USA. 3. Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA. 4. Charité Universitätsmedizin, Department of Child and Adolescent Psychiatry, Berlin, Germany. 5. Psychiatry and Biobehavioral Sciences, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, California, USA. 6. Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, New York, USA. 7. Thriving Mind South Florida Behavioral Health Network, Miami, Florida; and Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri, USA. 8. Department of Psychiatry, NYU Langone Medical Center, New York, and Nathan Kline Institute, Orangeburg, New York, USA. 9. Department of Psychiatry, University of Maryland School of Medicine, Baltimore, Maryland, USA. 10. Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. 11. Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, Division of Intramural Clinical and Biological Research, National Institute on Alcohol Abuse and Alcoholism, and Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland, USA. 12. Alexianer Hospital Aachen; and Department of Psychiatry, Psychotherapy and Psychosomatics, RWTH Aachen University; and JARA-Translational Brain Medicine, Aachen, Germany. 13. Servizio Psichiatrico del Comprensorio Sanitario di Bolzano, Bolzano, Italy. 14. Experimental Psychiatry Unit, Department of Psychiatry and Psychotherapy, Medical University of Innsbruck, Innsbruck, and Private Practice for Psychotherapy and Court-Certified Witness, Hall in Tirol, Austria. 15. Clinical Pharmacology, Department of Psychiatry and Psychotherapy, and Department of Pharmacology and Toxicology, University of Regensburg, Regensburg, Germany. 16. Department of Psychiatry, University of Lausanne, Prilly-Lausanne, Switzerland. 17. Department of Psychiatry and Psychotherapy and Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center of Mainz, Mainz, Germany. 18. Department of Molecular Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Authors: R Taurines; S Fekete; A Preuss-Wiedenhoff; A Warnke; C Wewetzer; P Plener; R Burger; M Gerlach; M Romanos; K M Egberts Journal: J Neural Transm (Vienna) Date: 2022-03-18 Impact factor: 3.850
Authors: Selene R T Veerman; Timo Moscou; Jan P A M Bogers; Dan Cohen; Peter F J Schulte Journal: Acta Psychiatr Scand Date: 2022-04-01 Impact factor: 7.734